Immunotherapy in lung cancer: effective for patients with poor performance status?

Lancet Respir Med. 2020 Sep;8(9):838-839. doi: 10.1016/S2213-2600(20)30107-7. Epub 2020 Mar 19.

Authors

Joao V Alessi¹, Mark M Awad²

Affiliations

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: mark_awad@dfci.harvard.edu.

PMID: 32199467
DOI: 10.1016/S2213-2600(20)30107-7

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Carcinoma, Non-Small-Cell Lung*
Humans
Immunotherapy
Lung Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab